Zydus Lifesciences gets USFDA nod for asthma drug Theophylline ER
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to market Theophylline Extended-Release Tablets, 300 mg and 450 mg (USRLD: Theo-Dur Extended-Release Tablets).
Theophylline is used to treat asthma and chronic obstructive pulmonary disease (COPD).
Asthma and chronic obstructive pulmonary disease (COPD) are both respiratory conditions that can cause breathing difficulties. Asthma is an inflammatory disorder of the airways, often triggered by allergens, irritants, or exercise. COPD, on the other hand, is primarily caused by long-term exposure to irritants like cigarette smoke, leading to chronic bronchitis and/or emphysema.
The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India. Theophylline Extended-Release Tablets, 300 mg and 450 mg had annual sales of USD 12.6 mn in the United States (IQVIA MAT March 24).
The group now has 396 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.